HC Wainwright Has Negative Outlook for CMPS FY2028 Earnings

COMPASS Pathways plc (NASDAQ:CMPS) – Investment analysts at HC Wainwright dropped their FY2028 earnings estimates for COMPASS Pathways in a report released on Thursday, February 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.14 for the year, down from their previous forecast of $0.24. HC Wainwright currently has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways’ FY2029 earnings at $1.63 EPS.

Other equities research analysts also recently issued research reports about the stock. Maxim Group cut their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $30.60.

COMPASS Pathways Trading Up 4.0 %

Shares of CMPS stock opened at $4.42 on Friday. The stock’s fifty day simple moving average is $4.10 and its 200-day simple moving average is $5.49. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways has a 1-year low of $3.16 and a 1-year high of $12.75.

Hedge Funds Weigh In On COMPASS Pathways

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. bought a new stake in COMPASS Pathways during the 4th quarter valued at approximately $41,000. Flagship Harbor Advisors LLC bought a new stake in shares of COMPASS Pathways in the fourth quarter valued at approximately $43,000. Wealthfront Advisers LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter worth $43,000. Conservest Capital Advisors Inc. grew its stake in shares of COMPASS Pathways by 28.9% in the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Simplify Asset Management Inc. bought a new position in COMPASS Pathways during the fourth quarter worth $54,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.